Several company developments were reported during the morning session, including FDA Breakthrough Therapy designation for 住友ファーマ's cancer drug and the introduction of a talent management tool by プラスアルファ.
住友ファーマ announced that its cancer drug enzomenib (development code DSP-5336) had received FDA Breakthrough Therapy designation for acute leukaemia with a KMT2A gene rearrangement that is relapsed or refractory. The company said it would advance development with the aim of obtaining early approval.
プラスアルファ・コンサルティング announced that it had introduced its talent management system, Talent Palette, at ケーズホールディングス. The system is intended to identify employees' strengths and aptitudes, promote the assignment of the right people to the right positions and advance employee development initiatives, as well as enhance store managers' personnel management capabilities.
北洋銀行 extended its gains after Nomura Securities changed its target price from ¥1,000 to ¥1,400. The move was attributed to higher interest income, a stable deposit base and gains across regional bank stocks. The bank was said to have confirmed improvements in deposit yields and higher interest income in its first-quarter results.
第一三共 plunged after the ESMO Congress suggested lower efficacy for Enhertu, its jointly developed cancer treatment. Meanwhile, positive results were reported for Merck's sacituzumab, and competitive developments were believed to have had an impact.
ラキール announced that its education service had been adopted by Kawasaki Kisen group company ダイトーコーポレーション, saying that the introduction of LaKeel Online Media Service would improve the effectiveness of training.
アンリツ raised its investment rating at SMBC Nikko Securities, which assessed demand for measuring instruments for optical transceivers as stronger than expected. Although the target price was revised downward, the investment rating was upgraded.